#tolerability — Tuesday, May 05, 2026 (1 items)
| 0 | 💬 0 |
'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.
(academic.oup.com)
|
Journal of Antimicrobial Chemotherapy 2026-05-05 | #metabolism #tolerability #hiv #virological suppression |